



## Research article

# Effects of EZH2 inhibitor, trichostatin A, and 5-azacytidine combinatorial treatment on osteogenic differentiation of dental pulp stem cells

Edit Hrubí<sup>a</sup>, László Imre<sup>b</sup>, Csaba Hegedüs<sup>a,\*</sup><sup>a</sup> Department of Biomaterials and Prosthetic Dentistry, Faculty of Dentistry, University of Debrecen, Debrecen, H-4032 Hungary<sup>b</sup> Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, H-4032, Hungary

## A B S T R A C T

**Objective:** Epigenetic mechanisms play regulatory roles in dental pulp stem cell (DPSC) differentiation. The molecules that modulate these mechanisms can be used to enhance DPSC differentiation in experimental studies and clinical applications. We investigated the combined effects of an epigenetic modulator enhancer of zeste homologue 2 inhibitor (EZH2i), trichostatin A (TSA), and 5-azacytidine (5-AZA) on the osteogenic differentiation of DPSCs.

**Results:** To assess osteogenic differentiation, we measured alkaline phosphatase activity, calcium deposition, and expression of osteogenic differentiation marker genes (*RUNX2*, *BMP2*, and *ALPL*) after 7 or 21 days of combinatorial drug treatment in normal cell culture medium or osteo-inductive medium (OIM). No synergistic effects were observed for any possible combination of EZH2i, TSA, or 5-AZA. However, the effects of these drugs and their combinations depend on the time and culture conditions.

**Discussion:** We confirmed that EZH2i and TSA have positive effects on the osteogenic differentiation of DPSCs. EZH2i activates the expression of key regulatory genes (*RUNX2*, *BMP2*, and *ALPL*) directly, whereas TSA interacts with signalling pathways induced by supplements in OIM to activate these genes.

## 1. Introduction

Dental pulp stem cells (DPSCs) isolated from the pulp of extracted adult wisdom teeth are a subtype of mesenchymal stem cells (MSCs) that exhibit multilineage differentiation potential [1–6]. The multipotency and easy and simple collection of DPSCs from pulp tissue make these cells promising candidates for tissue engineering in regenerative medicine [6] and an ideal *in vitro* model system to study stem cell differentiation. Among dental stem cells (DSCs), only DPSCs express all the key factors (OCT4, SOX2, and NANOG) that maintain pluripotency, suggesting that DPSCs have a better potential to differentiate into multiple cell types than other DSCs [7].

Stem cell differentiation is regulated not only at the genetic level via proteins that directly bind to different DNA motifs (e.g. transcription factors), but also via epigenetic mechanisms. These mechanisms involve DNA methylation and histone post-translational modifications, known as epigenetic markers. Components of chromatin remodelling complexes that act as writers, readers, and erasers of epigenetic marks are responsible for chromatin plasticity and dynamics [8–10]. Chromatin remodelling complexes regulate the reversible transition between the less compact, transcriptionally active euchromatin and the tightly packed, transcriptionally repressed heterochromatin, thus determining the pattern of actively transcribed genes in the whole genome [11,12].

In this study, we focused on the osteogenic differentiation of DPSCs and epigenetic mechanisms involved in this process. We and others have shown that DPSCs can differentiate into osteoblast progenitors and mature osteoblasts *in vitro* under culture conditions

\* Corresponding author.

E-mail address: [hegedus.csaba.prof@dental.unideb.hu](mailto:hegedus.csaba.prof@dental.unideb.hu) (C. Hegedüs).

conductive to osteogenic differentiation [5,6,13–20]. Distinct epigenetic mechanisms including histone acetylation, histone methylation, and DNA methylation regulate this process by modulating the expression of osteogenic marker genes [8–10].

Several epigenetic modifying agents have been developed for clinical use in cancer therapy to inhibit cell proliferation by modifying the function of chromatin remodelling complexes [21–23]. These agents also affect stem cell fate [24] and accelerate the osteogenic differentiation and mineralisation of DPSCs [24] opening novel possibilities for the application of these drugs. Given that DPSCs are promising candidates for tissue regeneration in dentistry and general medicine, it would be beneficial to enhance their osteogenic differentiation. Epigenetic-modifying agents can be used for this purpose if DPSCs are differentiated *in vitro* [6] or if drug treatment is combined with biodegradable polymers [25–29] as delivery systems to avoid side effects. In the present study, we examined three molecules: trichostatin A (TSA), enhancer of zeste homologue 2 inhibitor (EZH2i), and 5-azacytidine (5-AZA). TSA, a histone deacetylase inhibitor, increases chromatin acetylation by inhibiting histone deacetylases (HDACs), which are responsible for removing acetyl groups from lysine residues in the N-terminal tail of histone molecules. As histone acetylation is a characteristic feature of the promoter region of transcriptionally active genes, increased chromatin acetylation leads to general gene activation [30]. EZH2i hampers the histone methyltransferase activity of EZH2, the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is responsible for the methylation of the K27 residue in the H3 histone N-terminal tail. Trimethylation of K27 of histone H3 in gene promoters is a repressive epigenetic marker responsible for gene silencing [31]. Thus, similar to TSA, EZH2i treatment leads to gene activation across the entire genome. 5-AZA is a pyrimidine nucleoside analogue that can be incorporated into DNA. Because 5-AZA is incapable of accepting methyl groups from DNA methyltransferases, its incorporation leads to global hypomethylation of the genome and thus decondensation of heterochromatic regions, allowing inactive genes to be expressed [32]. Independent studies have shown that the osteogenic/odontogenic differentiation of DPSCs can be enhanced by these agents, modulating the epigenetic landscape of chromatin and thus activating key regulatory genes [33–37].

Although the effects of TSA, EZH2i, and 5-AZA on the osteogenic/odontogenic differentiation of DPSCs have been previously investigated, the combined effects of these drugs have not yet been studied. Thus, the aim of this study was to compare the effects of the three drugs in combination on the osteogenic differentiation of DPSCs and to reveal synergistic effects by measuring alkaline phosphatase (ALPL) activity, calcium deposition, and the expression of osteogenic differentiation marker genes, namely runt-related transcription factor 2 (*RUNX2*), bone morphogenetic protein 2 (*BMP2*), and *ALPL*.

## 2. Materials and methods

### 2.1. Cell culture

DPSCs were isolated from the pulp tissue of healthy human wisdom teeth based on a previously published protocol [38] (DPSCs were isolated from a 24-year-old male; patient declaration of agreement No. F0102/1ST). Isolated DPSCs were cultured in Dulbecco's Modified Eagle's Medium/F12 (DMEM-F12; 11320033; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10 % foetal bovine serum (FBS; F9665; Sigma-Aldrich, St. Louis, MO, USA), 100 units/mL penicillin, 100 mg/mL streptomycin (P0781; Sigma-Aldrich), and 1 % GlutaMAX (10567014; Life Technologies, Carlsbad, CA, USA) at 37 °C and 5 % CO<sub>2</sub> in a humidified atmosphere. In the figures, this medium is indicated as control medium (CM). Osteo-inductive medium (OIM) was prepared by supplementing CM with 10 mM β-glycerophosphate (G9891; Sigma-Aldrich), 50 µg/mL ascorbic acid (1043003; Sigma-Aldrich), 0.1 µM dexamethasone (D4902; Sigma-Aldrich), and 50 nM vitamin D3 (740292; Sigma-Aldrich). To induce epigenetic changes in the chromatin, CM or OIM was supplemented with 5 µM EZH2i (ab269816; Abcam, Cambridge, UK), 10 µM TSA (ab146598; Abcam), or 1 µM 5-AZA (ab142744; Abcam) alone or in combination.

### 2.2. Osteogenic differentiation

A total of 30,000 cells was seeded in each well of a 12-well cell culture plate (Z707775; Sigma-Aldrich) in 1 mL of CM. The cells were allowed to attach overnight in CM before treatment with OIM, CM, or media (CM or OIM) supplemented with EZH2i, TSA, 5-AZA, or their combination. In the case of 5-AZA, a 24-h treatment was applied on day 0; in the case of TSA and EZH2i, the treatment was continuous. The medium was changed every 2 days.

### 2.3. ALPL assay

After osteogenic induction, the cells were washed twice with 1 mL of 1 × phosphate-buffered saline (PBS) and lysed in lysis buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid [EDTA], 1 % Triton X-100, and 1 % protease inhibitor cocktail [PIC]). Scraped lysates were transferred to sterile Eppendorf tubes. After centrifugation (10,000×g for 10 min at 4 °C), the supernatant was used to determine ALPL activity and protein concentration (Pierce BCA Protein Assay; 23227; Thermo Fisher Scientific). To determine ALPL activity, 0.1 % *p*-nitrophenyl phosphate (N7653; Sigma-Aldrich; in 0.1 M glycine, 1 mM MgCl<sub>2</sub>, ZnCl<sub>2</sub>, pH 10.4) was added to the samples, and the absorbance was measured at 405 nm with a Hidex Sense Microplate reader (Hidex, Turku, Finland). The kinetic measurements were performed every 3 min for 2 h.

### 2.4. Measurement of calcium deposition

After osteogenic induction, the cells were washed twice with 1 mL of 1 × PBS (P5493; Sigma-Aldrich). The samples were fixed in 1

mL of ice-cold methanol (322415; Sigma-Aldrich) for 30 min at room temperature. Afterwards, the samples were dried for 5 min at room temperature and stained with 2 % (w/v) Alizarin Red S (pH 7; A5533; Sigma-Aldrich). For staining quantification, Alizarin Red S–calcium complexes were extracted with 10 % cetylpyridinium chloride (C0732; Sigma-Aldrich) diluted in 10 mM sodium phosphate buffer adjusted to pH 7 (P5244; Sigma-Aldrich), and the absorbance was measured at 570 nm using a Hidex Sense Microplate reader. For standardisation, the protein concentration of cell lysates was determined with the Pierce BCA Protein Assay (23227; Thermo Fisher Scientific) according to the manufacturer's instructions from parallel samples that were not stained with Alizarin Red S. Calcium deposition was expressed as A570 nm/ $\mu\text{g}$  protein.

### 2.5. Total RNA extraction, reverse transcription, and qPCR

After osteogenic induction, the cells were washed twice with 2 mL of  $1 \times$  PBS. Total RNA was extracted using a Quick-RNA Miniprep Kit (R1054; Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. The High-Capacity cDNA Reverse Transcription Kit (4368814; Thermo Fisher Scientific) was used to reverse transcribe 0.5  $\mu\text{g}$  of RNA per sample into cDNA.

Gene expression levels were determined using TaqMan gene expression assays for *RUNX2* (Hs00231692\_m1; Applied Biosystems, Waltham, MA, USA), *BMP2* (Hs00154192\_m1; Applied Biosystems), and *ALPL* (Hs01029144; Applied Biosystems), and were normalised to the reference housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*; Hs02758991; Applied Biosystems) in each sample. The 5x HOT FIREPOL Probe qPCR Mix Plus (no ROX; 08-15-00001; Solis BioDyne, Tartu, Estonia) was used for qPCR.


### 2.6. Statistical analysis

The error bars in the figures represent the standard deviations calculated from three independent measurements. One-way analysis of variance (ANOVA) with Dunnett's post hoc test was used for statistical analysis, where multiple comparisons were performed versus the control. Statistical significance was set at  $p < 0.05$ . The results of the statistical analyses and the data from which bar charts were generated are available in the supplementary materials.


## 3. Results

ALPL activity was measured in DPSCs after 7 or 21 days of culture in CM, OIM, CM, or OIM supplemented with different combinations of EZH2i, TSA, or 5-AZA (Fig. 1). Compared to untreated control DPSCs, ALPL activity increased on day 7 in DPSCs treated with EZH2i alone or in combination with TSA or 5-AZA in CM. After day 21 of treatment in CM, ALPL activity remained somewhat, but not significantly, higher in DPSCs treated with EZH2i alone or in combination with TSA, whereas 5-AZA treatment had a negative effect on ALPL activity. Short-(7 days) or long-term (21 days) treatment with TSA alone in CM had no effect on ALPL activity (Fig. 1A). In OIM, EZH2i increased ALPL activity in DPSCs after day 7 of treatment. TSA alone or in combination with other drugs was not effective at this time point, whereas 5-AZA had a negative effect similar to that of treatment with CM. Interestingly, at day 21, only DPSCs cultured in OIM with TSA showed increased ALPL activity; in contrast, EZH2i and 5-AZA decreased ALPL activity (Fig. 1B). No synergistic effects were observed for any drug combination in CM or OIM.


Alizarin Red S staining showed mineralisation of drug-treated DPSCs in OIM, but not in CM (Fig. 2). Calcium deposition is not expected in cells cultured in CM [13] because this medium does not contain inorganic phosphate. Surprisingly, mineralisation did not increase with any drug or combined drug treatment compared to OIM alone at days 7 and 21. In the presence of EZH2i, there was a remarkable decrease in mineralisation at day 21 when EZH2i was added alone or in combination with other drugs, in line with the reduction in ALPL activity.



**Fig. 1.** Measurement of ALPL activity (A) ALPL activity of DPSCs cultured in CM supplemented with TSA, 5-AZA, or EZH2i alone or in any possible combination, measured after days 7 and 21. (B) ALPL activity of DPSCs cultured in OIM supplemented with TSA, 5-AZA, or EZH2i alone or in any possible combination, measured after days 7 and 21. Height of bars represents mean, and error bars represent standard deviation of three independent experiments. One way ANOVA with Dunnett's post hoc test was used for statistical analysis ( $\alpha = 0.05$ ; # $p \leq 0.036$ ; \* $p \leq 0.001$ ), where drug treated samples were compared to untreated control.



**Fig. 2.** Measurement of mineralisation (A) Visualisation of calcium deposits of DPSCs cultured in OIM supplemented with TSA, 5-AZA, or EZH2i alone or in any possible combination, stained with Alizarin Red S, and measured after days 7 or 21. (B) Quantitative analysis of calcium-bound dye based on spectrophotometry. Height of bars represents mean, and error bars represent standard deviation of three independent experiments. One way ANOVA with Dunnett's post hoc test was used for statistical analysis ( $\alpha = 0.05$ ;  $*p < 0.001$ ), where drug treated samples were compared to untreated control.




**Fig. 3.** qPCR analysis of osteogenic marker genes (A) *RUNX2*, *BMP2*, and *ALPL* expression in DPSCs cultured in CM supplemented with TSA, 5-AZA, or EZH2i alone or in any possible combination, measured after day 21. (B) *RUNX2*, *BMP2*, and *ALPL* expression in DPSCs cultured in OIM supplemented with TSA, 5-AZA, or EZH2i alone or in any possible combination, measured after day 21. Height of bars represents mean, and error bars represent standard deviation of three independent experiments. One way ANOVA with Dunnett's post hoc test was used for statistical analysis ( $\alpha = 0.05$ ;  $\#p \leq 0.015$ ;  $*p \leq 0.001$ ), where drug treated samples were compared to untreated control.

Finally, we measured the expression of the *RUNX2*, *BMP2*, and *ALPL* osteogenic marker genes. After day 21, treatment with EZH2i alone or in combination with other drugs in CM had a positive effect on the expression of these genes (Fig. 3A). However, in OIMs, only TSA alone elevated these expression levels (Fig. 3B). EZH2i, alone or in combination with OIM, inhibited *RUNX2* and *BMP2* expression (Fig. 3B). These results are consistent and correlated with ALPL activity measurements. No synergistic effects were observed in any of the tested drug combinations.

#### 4. Discussion

Based on our data, TSA and EZH2i activated *RUNX2*, *BMP2*, and *ALPL* (Fig. 3), which are involved in the early stage of osteogenic differentiation, in agreement with published data [39,40]. Interestingly, EZH2i only affected these genes in DPSCs cultured in CM when the osteogenic differentiation signalling pathways were not activated by the components of OIM. This suggests that EZH2i can directly induce *RUNX2*, *BMP2*, and *ALPL* expression, which is in line with the chromatin immunoprecipitation sequencing (ChIP-seq) experiments demonstrating that these genes are specific targets of EZH2 [41]. The OIM constituents  $\beta$ -glycerophosphate, ascorbic acid, vitamin D3, and dexamethasone interfere with the action of EZH2i. Among these agents, dexamethasone [42] and vitamin D3 [43,44] can activate the Wnt/ $\beta$ -catenin signalling pathway, which is involved in the regulation of osteogenic differentiation, either enhancing [42–44] or inhibiting this process. WNT1 inhibits the odontogenic differentiation of DPSCs [45], and WNT1 and WNT3A inhibit the osteogenic differentiation of human MSCs [46–48]. Given that WNT1 and WNT3A are EZH2 targets [41], EZH2i treatment may release the repressed state of these genes, leading to decreased ALPL activity and lack of mineralisation (Figs. 1 and 2), similar to WNT1 treatment [45]. The BMP antagonists noggin [49] and chordin [50] are also regulated by EZH2-dependent H3K27 methylation [41, 51]. Noggin and chordin can bind to BMPs that are expressed and secreted as autocrine signals during osteogenic differentiation, inhibiting their binding to BMP receptors and activating BMP-induced signalling pathways. Among the EZH2 targets [41], HDACs also inhibit osteogenic differentiation by deacetylating histones at the promoter region of the key regulator genes *RUNX2*, *BMP2*, and *ALPL* [41], which encode signalling pathway-related proteins [41], or by directly binding to *RUNX2* [52].

In contrast to EZH2i, TSA was effective in OIM culture conditions permissive for osteogenic differentiation, but not in CM, suggesting that TSA has no direct effect on *RUNX2*, *BMP2*, and *ALPL* expression, although these genes are specific targets of HDAC1, HDAC2, and HDAC6 [41]. Rather, TSA acts on these genes through other genes activated by or involved in signalling pathways induced by OIM supplements, such as WNT, BMP, BMP receptor, SMAD, and MAPK, which are also HDAC targets [41]. Treatment with dexamethasone leads to the expression of *RUNX2* and its co-activator, the transcriptional co-activator with PDZ-binding motif (*TAZ*) [42], another target of HDACs [41]. Dexamethasone treatment also induces the expression of mitogen-activated protein kinase phosphatase 1 (*MKP1*) and collagen type 1 (*COL1*) [42], an HDAC target [41] that encodes an extracellular matrix protein important for mineralisation. *MKP1* dephosphorylates *RUNX2*, which is required for *TAZ* binding [42]. Ascorbic acid plays a role in *COL1* secretion, and integrins can activate the MAPK signalling pathway, leading to the accumulation of the phosphorylated form of extracellular signal-regulated kinase (pERK) in the nucleus. Together with *RUNX2*, pERK binds to osteocalcin (*OCN*) and bone sialoprotein (*BSP*), which are responsible for mineralisation in the late stage of osteogenic differentiation [42].  $\beta$ -Glycerophosphate serves as a phosphate source needed for hydroxyapatite ( $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ) production during mineralisation. Furthermore, phosphate can enter cells where it regulates the expression of osteopontin (*OPN*) and *BMP2*, acting as an intracellular signalling molecule [42].



**Fig. 4.** Possible mechanisms of action of EZH2i and TSA on osteogenic differentiation of DPSCs. EZH2i and TSA act via distinct mechanisms involving direct (arrow with a solid line) or indirect effects (arrow with a dashed line) on expression of key regulatory genes *RUNX2*, *BMP2*, and *ALPL*. EZH2i may also activate genes that counteract osteogenic differentiation by inhibiting BMP signalling (*NOG* and *CHRD*), reducing *ALPL* expression (*WNT1* and *WNT3A*), or deacetylating key regulatory and signalling pathway genes (*HDACs*).

Because mineralisation was not affected, TSA had no effect on genes responsible for mineralisation activated in the late stage of differentiation, a finding consistent with the ChIP-seq data showing that the *OCN*, *OPN*, and *BSP* genes are not specific targets of HDACs [41].

5-AZA had no positive effect on DPSC differentiation when administered alone or in combination with other drugs; these results differ from published data [37]. This contradiction could be the result of the suboptimal dosage of 5-AZA, or that this drug may be incorporated into DNA as well as RNA, in contrast to the 5-aza-2-deoxycytidine used by Zhang et al. [37]. The heterogeneity of DPSCs isolated from the same [2] or different [53] donors may have also led to inconsistent conclusions from independent studies. Kobayashi et al. [2] showed striking variability in the proliferation, cell surface marker expression patterns, and odontogenic, adipogenic, and chondrogenic differentiation potentials of single cell-derived clones of DPSCs obtained from the same donor. Macrin et al. [53] showed that the osteogenic potential of slow and rapid aging DPSCs vary depending on the upregulation of the TGF- $\beta$  pathway and cytoskeletal proteins as well as on the metabolic state of the cells, which can differ among DPSCs originating from different donors. The effects of epigenetic modulators may also differ in DPSCs isolated from different donors, which is a limitation of this study because DPSCs were isolated from only one patient.

## 5. Conclusions

There were no synergistic effects when TSA, EZH2i, and 5-AZA drug combinations were applied, and only TSA had positive effects on the expression of early osteogenic marker genes and alkaline phosphatase activity, but had no effect on mineralisation under culture conditions permissive for osteogenic differentiation. Based on the present study, we hypothesise that these drugs act via distinct mechanisms involving a direct or indirect effect by EZH2i or TSA, respectively, on the expression of the key regulatory genes *RUNX2*, *BMP2*, and *ALPL*, and thus on osteogenic differentiation (Fig. 4) which requires further investigation. Because EZH2i showed inhibitory effects, TSA would be a better choice for medical applications aimed at bone regeneration; however, the effects of epigenetic modulators may vary among DPSCs originating from different patients. Thus, comparative studies with an increased number of donors are needed.

## Data availability statement

No data has been deposited into a publicly available repository.

## CRedit authorship contribution statement

**Edit Hrubí:** Writing – original draft, Visualization, Investigation. **László Imre:** Writing – review & editing. **Csaba Hegedüs:** Supervision, Funding acquisition, Conceptualization.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgments

The research supported by project no. TKP2021-EGA-20 (Biotechnology) was implemented with support provided by the National Research, Development and Innovation Fund of Hungary, financed under the TKP2021-EGA funding scheme.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at doi:mmedoio

## References

- [1] E. Ledesma-Martinez, V.M. Mendoza-Nunez, E. Santiago-Osorio, Mesenchymal stem cells derived from dental pulp: a review, *Stem Cell. Int.* 2016 (2016) 4709572.
- [2] T. Kobayashi, et al., Characterization of proliferation, differentiation potential, and gene expression among clonal cultures of human dental pulp cells, *Hum. Cell* 33 (3) (2020) 490–501.
- [3] S. Gronthos, et al., Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo, *Proc. Natl. Acad. Sci. U. S. A.* 97 (25) (2000) 13625–13630.
- [4] X. Shi, J. Mao, Y. Liu, Pulp stem cells derived from human permanent and deciduous teeth: biological characteristics and therapeutic applications, *Stem Cells Transl Med* 9 (4) (2020) 445–464.
- [5] M. Aurrekoetxea, et al., Dental pulp stem cells as a multifaceted tool for bioengineering and the regeneration of craniomaxillofacial tissues, *Front. Physiol.* 6 (2015) 289.
- [6] A. Soudi, et al., Role and application of stem cells in dental regeneration: a comprehensive overview, *EXCLI J* 20 (2021) 454–489.

- [7] A.V. Kotova, et al., Comparative analysis of dental pulp and periodontal stem cells: differences in morphology, functionality, osteogenic differentiation and proteome, *Biomedicines* 9 (11) (2021).
- [8] D. Bayarsaihan, Deciphering the epigenetic code in embryonic and dental pulp stem cells, *Yale J. Biol. Med.* 89 (4) (2016) 539–563.
- [9] D. Zhou, et al., Epigenetic regulation of dental pulp stem cell fate, *Stem Cell. Int.* 2020 (2020) 8876265.
- [10] A. Hussain, H. Tebyaniyan, D. Khayatan, The role of epigenetic in dental and oral regenerative medicine by different types of dental stem cells: a comprehensive overview, *Stem Cell. Int.* 2022 (2022) 5304860.
- [11] S.L. Klemm, Z. Shipony, W.J. Greenleaf, Chromatin accessibility and the regulatory epigenome, *Nat. Rev. Genet.* 20 (4) (2019) 207–220.
- [12] C.R. Clapier, et al., Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes, *Nat. Rev. Mol. Cell Biol.* 18 (7) (2017) 407–422.
- [13] E. Hrubí, et al., Diverse effect of BMP-2 homodimer on mesenchymal progenitors of different origin, *Hum. Cell* 31 (2) (2018) 139–148.
- [14] F. Toth, et al., Effect of inducible bone morphogenetic protein 2 expression on the osteogenic differentiation of dental pulp stem cells in vitro, *Bone* 132 (2020) 115214.
- [15] F. Toth, J. Tozser, C. Hegedus, Effect of inducible BMP-7 expression on the osteogenic differentiation of human dental pulp stem cells, *Int. J. Mol. Sci.* 22 (12) (2021).
- [16] M.N. Hagar, et al., Comparative evaluation of osteogenic differentiation potential of stem cells derived from dental pulp and exfoliated deciduous teeth cultured over granular hydroxyapatite based scaffold, *BMC Oral Health* 21 (1) (2021) 263.
- [17] G. Mori, et al., Dental pulp stem cells: osteogenic differentiation and gene expression, *Ann. N. Y. Acad. Sci.* 1237 (2011) 47–52.
- [18] S. Awais, et al., Human dental pulp stem cells exhibit osteogenic differentiation potential, *Open Life Sci.* 15 (2020) 229–236.
- [19] J. Sabbagh, et al., Differences in osteogenic and odontogenic differentiation potential of DPSCs and SHED, *J. Dent.* 101 (2020) 103413.
- [20] B. Choi, et al., Sphingosine-1-phosphate hinders the osteogenic differentiation of dental pulp stem cells in association with AKT signaling pathways, *Int. J. Oral Sci.* 14 (1) (2022) 21.
- [21] A. Ganesan, et al., The timeline of epigenetic drug discovery: from reality to dreams, *Clin. Epigenet.* 11 (1) (2019) 174.
- [22] S. Ghasemi, Cancer's epigenetic drugs: where are they in the cancer medicines? *Pharmacogenomics J.* 20 (3) (2020) 367–379.
- [23] S. Heerboth, et al., Use of epigenetic drugs in disease: an overview, *Genet. Epigenet.* 6 (2014) 9–19.
- [24] H.F. Duncan, et al., Epigenetic modulation of dental pulp stem cells: implications for regenerative endodontics, *Int. Endod. J.* 49 (5) (2016) 431–446.
- [25] S.A. Mosaddad, et al., Fabrication and properties of developed collagen/strontium-doped Bioglass scaffolds for bone tissue engineering, *J. Mater. Res. Technol.* 9 (6) (2020) 14799–14817.
- [26] E. Tafazoli Moghadam, et al., Current natural bioactive materials in bone and tooth regeneration in dentistry: a comprehensive overview, *J. Mater. Res. Technol.* 13 (2021) 2078–2114.
- [27] R.S. Soufdoost, et al., In vitro and in vivo evaluation of novel Tadalafil/ $\beta$ -TCP/Collagen scaffold for bone regeneration: a rabbit critical-size calvarial defect study, *Biocybern. Biomed. Eng.* 39 (3) (2019) 789–796.
- [28] M. Yazdaniyan, et al., Fabrication and properties of  $\beta$ TCP/Zelite/Gelatin scaffold as developed scaffold in bone regeneration: in vitro and in vivo studies, *Biocybern. Biomed. Eng.* 40 (4) (2020) 1626–1637.
- [29] H. Tebyaniyan, et al., Effects of collagen/beta-tricalcium phosphate bone graft to regenerate bone in critically sized rabbit calvarial defects, *J. Appl. Biomater. Funct. Mater.* 17 (1) (2019) 2280800018820490.
- [30] C.B. Yoo, P.A. Jones, Epigenetic therapy of cancer: past, present and future, *Nat. Rev. Drug Discov.* 5 (1) (2006) 37–50.
- [31] R. Duan, W. Du, W. Guo, EZH2: a novel target for cancer treatment, *J. Hematol. Oncol.* 13 (1) (2020) 104.
- [32] T. Haaf, The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes, *Pharmacol. Ther.* 65 (1) (1995) 19–46.
- [33] H. Jin, et al., HDAC inhibitor trichostatin A promotes proliferation and odontoblast differentiation of human dental pulp stem cells, *Tissue Eng.* 19 (5–6) (2013) 613–624.
- [34] H.F. Duncan, et al., Histone deacetylase inhibitors epigenetically promote reparative events in primary dental pulp cells, *Exp. Cell Res.* 319 (10) (2013) 1534–1543.
- [35] B. Li, et al., EZH2 impairs human dental pulp cell mineralization via the wnt/beta-catenin pathway, *J. Dent. Res.* 97 (5) (2018) 571–579.
- [36] T. Hui, et al., EZH2, a potential regulator of dental pulp inflammation and regeneration, *J. Endod.* 40 (8) (2014) 1132–1138.
- [37] D. Zhang, et al., Effect of 5-Aza-2'-deoxycytidine on odontogenic differentiation of human dental pulp cells, *J. Endod.* 41 (5) (2015) 640–645.
- [38] K. Kadar, et al., Differentiation potential of stem cells from human dental origin - promise for tissue engineering, *J. Physiol. Pharmacol.* 60 (Suppl 7) (2009) 167–175.
- [39] M. Montecino, M.E. Carrasco, G. Nardocci, Epigenetic control of osteogenic lineage commitment, *Front. Cell Dev. Biol.* 8 (2020) 611197.
- [40] L. Oton-Gonzalez, et al., Genetics and epigenetics of bone remodeling and metabolic bone diseases, *Int. J. Mol. Sci.* 23 (3) (2022).
- [41] A.D. Rouillard, et al., The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins, *Database* (2016) 2016.
- [42] F. Langenbach, J. Handschel, Effects of dexamethasone, ascorbic acid and beta-glycerophosphate on the osteogenic differentiation of stem cells in vitro, *Stem Cell Res. Ther.* 4 (5) (2013) 117.
- [43] Y. Xiong, et al., 1 $\alpha$ ,25-Dihydroxyvitamin D(3) promotes osteogenesis by promoting Wnt signaling pathway, *J. Steroid Biochem. Mol. Biol.* 174 (2017) 153–160.
- [44] J. van de Peppel, J.P. van Leeuwen, Vitamin D and gene networks in human osteoblasts, *Front. Physiol.* 5 (2014) 137.
- [45] E.L. Scheller, J. Chang, C.Y. Wang, Wnt/beta-catenin inhibits dental pulp stem cell differentiation, *J. Dent. Res.* 87 (2) (2008) 126–130.
- [46] G.M. Boland, et al., Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells, *J. Cell. Biochem.* 93 (6) (2004) 1210–1230.
- [47] J. de Boer, et al., Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells, *Bone* 34 (5) (2004) 818–826.
- [48] H.H. Cho, et al., Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells, *Tissue Eng.* 12 (1) (2006) 111–121.
- [49] D.C. Wan, et al., Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation, *J. Biol. Chem.* 282 (36) (2007) 26450–26459.
- [50] F.N. Kwong, S.M. Richardson, C.H. Evans, Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells, *Arthritis Res. Ther.* 10 (3) (2008) R65.
- [51] N. Akizu, et al., H3K27me3 regulates BMP activity in developing spinal cord, *Development* 137 (17) (2010) 2915–2925.
- [52] E.D. Jensen, et al., Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner, *J. Bone Miner. Res.* 23 (3) (2008) 361–372.
- [53] D. Macrin, et al., Metabolism as an early predictor of DPSCs aging, *Sci. Rep.* 9 (1) (2019) 2195.